01854nas a2200313   4500000000100000008004100001260001300042653003300055653001100088653001700099653001200116653002400128653000900152653002200161653001700183100001400200700001400214700001400228700001500242700002300257700001500280245013100295856005900426300001100485490000700496050001400503520100900517022001401526       1989                            d  c1989 Jun10aFollicle Stimulating Hormone10aHumans10aHypogonadism10aleprosy10aLuteinizing Hormone10aMale10aRandom Allocation10aTestosterone1 aLevis W R1 aLanza A P1 aSwersie S1 aMeeker H C1 aSchuller-Levis G B1 aBardin C W00aTesticular dysfunction in leprosy: relationships of FSH, LH and testosterone to disease classification, activity and duration.  uhttp://leprev.ilsl.br/pdfs/1989/v60n2/pdf/v60n2a02.pdf  a94-1010 v60  aLEVIS19893 a<p>Luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone levels were determined by radioimmunoassay (RIA) in leprosy patients and analysed for effect of disease classification, disease activity and duration of disease. LH and FSH levels were found to be significantly elevated in lepromatous patients compared to borderline-lepromatous, midborderline and borderline-tuberculoid patients. A positive correlation was seen between LH and FSH and a negative correlation was seen between testosterone and both LH and FSH. No correlation was seen between hormone levels and measures of disease activity: bacillary index and IgM to phenolic glycolipid I, a Mycobacterium leprae antigen. A significant correlation was seen between duration of disease and FSH when age was taken into account, indicating that testicular dysfunction is probably cumulative and irreversible. It is recommended that LL patients be routinely screened for hypogonadism using FSH, LH and testosterone levels.</p>  a0305-7518